相关实验视频

Updated: Feb 22, 2026

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Assessing Early Stage Open-Angle Glaucoma in Patients by Isolated-Check Visual Evoked Potential

Published on: May 25, 2020

一个探索性研究六个月的尼亚辛胺补充剂在初级开放角度玻璃眼中的斑点结构和电生理学

Constantin Alin Nicola¹, Maria Cristina Marinescu², Cristina Alexandrescu³

¹Doctoral School, University of Medicine and Pharmacy of Craiova, 200349 Craiova, Romania.

Vision (Basel, Switzerland)

|February 20, 2026

概括

六个月的尼亚辛胺补充剂在初级开角玻璃眼 (POAG) 患者的视力没有显著改善或恶化. 这项研究强调了针对未来青光眼神经保护试验的特定分析方法的重要性.

科学领域:

眼科和神经科学眼科和神经科学
神经保护和视觉科学科学神经保护和视觉科学

背景情况:

主要开角青光眼 (POAG) 是不可逆转的失明的主要原因,往往无症状,直到晚期.
目前的治疗重点是降低眼内压力,神经保护是新兴的治疗策略.
尼亚辛胺 (维生素B3) 是NAD+的前体,在临床前的玻璃眼模型中显示出潜在的神经保护作用.

研究的目的:

评估口服尼亚胺补充剂对POAG患者的短期功能,结构和电生理效应.
评估氨酸胺在POAG人群中的安全性和潜在的神经保护作用.

主要方法:

一项干预性研究涉及POAG患者,他们每天接受500毫克口服尼亚辛胺,持续6个月.
视野 (VF) 灵敏度 (MD,PSD),光学连贯性断层扫描 (OCT) 参数 (RNFL,GCC) 和视觉唤起潜力 (VEP) 在基线和六个月的评估.
使用通用估计方程 (GEE) 和线性混合效应模型进行纵向推断,以解释眼睛之间的相关性.

主要成果:

在视野的平均偏差 (MD) 或模式标准偏差 (PSD) 中没有观察到统计学意义上的变化.
视网膜神经纤维层 (RNFL) 厚度略有下降,而质细胞复合体 (GCC) 保持稳定.
视觉唤起潜能 (VEP) P100延迟稳定,但P2延迟显示出小幅增加;没有检测到临床上有意义的进展或改善.

结论:

在POAG患者中服用尼胺胺补充剂6个月后,其整体功能,结构和电生理学稳定性得到证明.
这项研究支持氨酸胺对POAG的短期安全性.
这些发现强调了聚类分析方法和以黄斑为中心的生物标志物在未来的玻璃眼神经保护研究中的重要性.

关键词:

玻璃眼 glaucoma 玻璃眼玻璃眼玻璃眼玻璃眼氨酸胺是什么意思尼古丁胺胺是什么尼古丁胺胺是什么光学连贯性断层扫描技术视野视野视野视野视野在视觉上唤起的潜能.维生素B3 维生素B3 是一种维生素.

更多相关视频

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Regenerative Therapy by Suprachoroidal Cell Autograft in Dry Age-related Macular Degeneration: Preliminary In Vivo Report

Published on: February 12, 2018

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

A Magnetic Microbead Occlusion Model to Induce Ocular Hypertension-Dependent Glaucoma in Mice

Published on: March 23, 2016

相关概念视频

Open Angle Glaucoma: Treatment

Open Angle Glaucoma: Treatment

In open-angle glaucoma, the iridocorneal angle remains open, but the trabecular meshwork becomes stiff, slowing down the outflow of aqueous humor. This causes a buildup of aqueous humor in the anterior chamber, leading to a sudden increase in intraocular pressure. The treatment for open-angle glaucoma focuses on reducing the elevated intraocular pressure by either decreasing the secretion of aqueous humor or increasing its outflow.
Drugs such as carbonic anhydrase inhibitors, α2- and...

Angle Closure Glaucoma: Treatment

Angle Closure Glaucoma: Treatment

Angle-closure glaucoma, or closed-angle glaucoma, is an eye condition where the iris bulges out and blocks the iridocorneal angle, resulting in a buildup of aqueous humor and increased intraocular pressure. Immediate medical attention is necessary due to the sudden onset of symptoms. The treatment for angle-closure glaucoma includes short-term and long-term approaches. Short-term treatment involves using eye drops like pilocarpine to lower intraocular pressure by increasing aqueous humor...

Glaucoma: Overview

Glaucoma: Overview

Glaucoma is an eye condition characterized by increased intraocular pressure that damages the retina and optic nerve, leading to irreversible blindness if left untreated. The human eye has various components, including the cornea, iris, pupil, lens, and optic nerve. Aqueous humor is secreted by the epithelium of the ciliary body in the posterior chamber and flows through the trabecular meshwork and canal of Schlemm, maintaining normal intraocular pressure. The trabecular meshwork and the canal...